Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has received an average rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $5.89.

Several analysts recently issued reports on the company. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Anthera Pharmaceuticals in a research note on Tuesday, September 19th. Finally, ValuEngine raised Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wedbush Securities Inc. increased its stake in Anthera Pharmaceuticals by 75.8% in the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 31,800 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Anthera Pharmaceuticals by 1,376.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 335,595 shares during the last quarter. Finally, UBS Group AG increased its stake in Anthera Pharmaceuticals by 9.9% in the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 33,901 shares during the last quarter. 16.24% of the stock is currently owned by institutional investors.

Shares of Anthera Pharmaceuticals (ANTH) traded up $0.02 on Friday, reaching $1.50. The company had a trading volume of 383,684 shares, compared to its average volume of 344,632. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $17.04.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.32. During the same period in the prior year, the company posted ($4.85) EPS. equities analysts forecast that Anthera Pharmaceuticals will post -3.14 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/anthera-pharmaceuticals-inc-anth-receives-consensus-recommendation-of-hold-from-brokerages/1762182.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.